Potential biomarkers and drugs for common breast cancer
Professor Arne 脰stman in CCBIO's International Faculty receives financial support from the Western Norway regional health authorities Helse Vest in their 2023 allocation. His project "Novel biomarkers and combination treatments for ER+ breast cancer" receives NOK 1.500.000 in the first year.
Main content
Arne 脰stman has been a member of the since its startup.
Does聽fibroblast subsets control ER+ breast cancer?
Among breast cancers, the Estrogen Receptor-positive (ER+) is the most common group. Improved diagnostics and novel drugs have improved outcome. However, better biomarkers and drugs are needed for this large patient group.聽
Cancer-associated fibroblasts is a poorly characterized cell type controlling tumor aggressiveness and response to treatment through communications with malignant cells and immune cells. This project tests the overall hypothesis that novel to-be-defined fibroblast subsets control ER+ breast cancer through interactions with malignant cells and immune cells, and thereby are potential biomarkers and drug targets.
Defining features of the application include:聽
- usage of highly competitive resources and methodologies, e.g. advanced tissue analyses methods, trial-derived tumor collections, and novel drug screening formats聽
- collaborations with established partners with relevant and leading expertise in breast cancer pathology, biomarker studies, and drug screening聽
- high originality ensured by development of original recent published and up-published research findings of 脰stman
Studies will provide findings that will advance clinical management of ER+ breast cancer through discovery of improved biomarkers and drugs with novel mechanisms of action.
Norwegian-Swedish collaboration
The study will be performed through close collaborations with the group of Professor Lars A. Akslen, CCBIO/幸运飞艇计划 and Swedish breast cancer experts. Additional key partners are the and the at the SciLifeLab, Stockholm.聽
Read more about the聽听(狈辞谤飞别驳颈补苍).
